Targeting the eicosanoid pathway in non-small-cell lung cancer.
Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2) upregulation is an early event in the development of non-small-cell lung cancer. Preclinical data indicate tumors with upregulation of COX-2 synthesize high levels of prostaglandin E₂ (PGE₂), which in turn are associated with increased production of proangiogenic factors and enhanced metastatic potential. These findings indicate that an increase in COX-2 expression may play a significant role in the development and growth of lung cancers and possibly with the acquisition of an invasive and metastatic phenotype. Consequently, inhibitors of COX-2 are being studied for their chemopreventative and therapeutic effects in individuals at high risk for lung cancer and patients with established cancers.
Horn
Leora
L
Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Division of Hematology & Medical Oncology, 2220 Pierce Avenue, Nashville, TN 37232, USA.
Backlund
Michael
M
Johnson
David H
DH
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism*; D051546:Cyclooxygenase 2 / Q000235:genetics / Q000378:metabolism*; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D015777:Eicosanoids / Q000378:metabolism*; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D015854:Up-Regulation
D000970:Antineoplastic Agents; D052246:Cyclooxygenase 2 Inhibitors; D015777:Eicosanoids; D051546:Cyclooxygenase 2